首页 › 急性髓系白血病 › 堪萨斯州 › Kansas City
Kansas City KS 急性髓系白血病临床试验
12项针对 急性髓系白血病的研究正在 Kansas City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Ivosidenib as Post-HSCT Maintenance for AML
招募中2 期
- Kansas University Medical Center, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 距离 21 英里
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
招募中3 期
- US-Kansas City KS-KUMC, Kansas City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- University of Kansas Cancer Center, Kansas City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- The University of Kansas Cancer Center, Kansas City
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
招募中1 期
- University of Kansas Medical Center Research Institute, Inc., Kansas City
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
招募中1 期
- KU Cancer Center, Kansas City
其他城市的 急性髓系白血病试验
- Houston, TX85 项研究
- New York City, NY51 项研究
- Boston, MA44 项研究
- Seattle, WA41 项研究
- Baldwin Park, CA40 项研究
- Columbus, OH35 项研究
- Philadelphia, PA34 项研究
- Durham, NC33 项研究
- Atlanta, GA31 项研究
- Tampa, FL29 项研究
- Chicago, IL26 项研究
- Portland, OR25 项研究
Kansas City的其他研究
- 心血管疾病14 项研究
- 心力衰竭13 项研究
- 肥胖症13 项研究
- 间质性肺病13 项研究
- 囊性纤维化13 项研究
- 乳腺癌12 项研究
- 膀胱癌12 项研究
- 前列腺癌12 项研究
- 非小细胞肺癌11 项研究
- 肺癌11 项研究
- 慢性阻塞性肺病9 项研究
- 哮喘8 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。